

## CURRICULUM VITAE

**Name** | **Alessandro Colapietro**

**Home Address** | Via Conte Appiano 20, Foggia

**Work Address** | Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila,  
Via Vetoio, Coppito 2, 67100 L'Aquila

**Telephone**

**Mobile** | +39 328 9062956

**Fax**

**E-mail** | alecolapietro@gmail.com

**Nationality** | Italian

**Date of birth** | 10/05/1988

### Education

- Dates | October 2014
- Title of qualification awarded | **M.S. In Medical Biotechnology, 110/110 e lode**
- Name and type of organization providing education and training | Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila
  
- Dates | March 2012
- Title of qualification awarded | **Bachelor's degree in Biotechnology, 108/110**
- Name and type of organization providing education and training | Department of Biomedical Sciences and Technologies, University of L'Aquila

### Work experiences

- Dates | November 2014 – to November 2017
- Occupation or position held | **PhD student**
- Name and address of employer | Department of Biotechnological and Applied Clinical Science, University of L'Aquila
- Main activities and responsibilities | Preclinical investigation of the in vivo and in vitro effects of anti-target compounds on different cancer models, such as Glioma, Prostate cancer, and Colorectal cancer, alone and in combination with ionizing radiation.

**Active participation to training courses**

Training course

•Activities

•Dates

•Name and type of organization

**Training and updating course in the field of use animals for scientific and educational fines**

29/11/2016-07/12/2016

CIFIV, Teramo (TE)

Training course

•Activities

•Dates

•Name and type of organization

**Training in orthotopic intraprostatic inoculation of cancer cells in mouse model.**

26/2/2015

Fondazione IRCCS ISTITUTO NAZIONALE DEI TUMORI, Milan (MI)

**Participation to congress and meetings**

**As invited speaker**

Meeting

•Activities

•Dates

•Name and type of organization

**As participant**

- “30<sup>th</sup> Annual Conference of Italian Association of Cell cultures” Mila, Novembe27-28, 2017.
- “ABCD Congress 2017”. Bologna, 23/09/2017
- “The future of cancer therapy: the genome editing Era” University Magna Graecia, Catanzaro, 8-9 June 2017
- “29<sup>th</sup> Annual Conference of Italian Association of Cell Cultures” Crossroads in cellular and molecular Biotechnology (Novel Diagnostic and Therapeutic Strategies for Cancer, immunological Disorder and Rare Disease). L’Aquila 23-25 November 2016
- “58<sup>th</sup> Annual Meeting of The Italian Cancer Society” REVOLUTIONARY ROAD- Accelerating conversion of cancer biology into personalized clinical oncology. Verona September 5-8 2016.
- “First congress on the Eph/ephrin system-state of the art, challenges and opportunities”. Parma May 5-6, 2016
- “XXV national congress SIUrO”. Roma,21-23 June 2015

**Competences and Technical skills**

- Biochemical techniques (western blot, immunoprecipitation, ELISA, zymography)
- In vitro and in vivo efficacy analysis of natural and synthetic compounds with antitumor activity.
- Signal transduction investigations
- Animal manipulation and treatment

**Mother language**

Italian

**Other languages**

English

**Posters/Abstracts**

- EPHA2 inhibition reverts epithelial-mesenchymal transition (EMT) phenotype and reduces proliferation of colorectal cancer cells. Alessandro Colapietro, A. Mancini, S. Martellucci, V. Mattei, G.L. Gravina, F. Berinckx, P. Pujuguet, L. Saniere, E. van der Aar, G. Lorenzon, C. FestucciA. Conference: Conference: 29th Annual conference of Italian association of cell cultures, At L'Aquila

Gravina, GL (Gravina, Giovanni Luca), Mancini, A (Mancini, Andrea), Colapietro A, Marampon, F (Marampon, Francesco), Sanita, P (Sanita, Patrizia), Delle Monache, S (Delle Monache, Simona), Festuccia, C (Festuccia, Claudio) (2016). STROMAL-EPITHELIAL INTERACTIONS REGULATE THE INFLAMMATORY STATUS OF PROSTATE CANCER TISSUE: NEW THERAPEUTICAL TARGETS FOR LOCALLY AGGRESSIVE TUMORS . ANTICANCER RESEARCH, ISSN: 0250-7005

2015

Gravina, GL (Gravina, Giovanni Luca), Mancini, A (Mancini, Andrea), Colapietro A, Scarsella, L (Scarsella, Luca), Jitariuc, A (Jitariuc, Ana), Delle Monache, S (Delle Monache, Simona), Di Cesare, E (Di Cesare, Ernesto), Richardson, PJ (Richardson, Peter J.), Patient, L (Patient, Lee), Burbidge, S (Burbidge, Stephen), Festuccia, C

**(Festuccia, Claudio) (2015). Blockade of the SDF-1/CXCR4 axis is additive/synergistic with radiotherapy and/or temozolomide treatment both in vitro and in vivo in preclinical models of glioblastoma . INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, ISSN: 1107-3756**

**2015**

**Gravina, GL (Gravina, Giovanni L.), Mancini, A (Mancini, Andrea), Colapietro A, Monache, SD (Monache, Simona D.), Angelucci, A (Angelucci, Adriano), Calgani, A (Calgani, Alessia), Fogler, WE (Fogler, William E.), Magnani, JL (Magnani, John L.),Festuccia, C (Festuccia, Claudio) (2015). Dual E-selectin and CXCR4 inhibition reduces tumor growth and increases the sensitivity to docetaxel in experimental bone metastases of prostate cancer . CANCER RESEARCH, ISSN: 0008-5472**

**2015**

**Gravina, GL (Gravina, Giovanni Luca), Colapietro A, Delle Monache, S (Delle Monache, Simona), Angelucci, A (Angelucci, Adriano), Calgani, A (Calgani, Alessia), Sanita, P (Sanita, Patrizia), Fogler, WE (Fogler, William E.), Magnani, JL (Magnani, John L.), Festuccia, C (Festuccia, Claudio) (2015). METASTATIC PROPERTIES AND RESISTANCE TO DOCETAXEL ARE INHIBITED BY ANTAGONISM OF CXCR4 AND E-SELECTIN IN EXPERIMENTAL PROSTATE CANCERS MIMICKING A TUMOR WITH HIGH RISK TO DEVELOP METASTASES OR GROWING IN BONE MICROENVIRONMENT . ANTICANCER RESEARCH, ISSN: 0250-7005**

**2015**

**Gravina, GL (Gravina, Giovanni Luca), Marampon, F (Marampon, Francesco), Colapietro A, Scarsella, L (Scarsella, Luca), Jitariuc, A (Jitariuc, Ana), Sanita, P (Sanita, Patrizia), Sherris, D (Sherris, David), Festuccia, C (Festuccia, Claudio) (2015). RES529, A DUAL TORC1/TORC2 INHIBITOR, POTENTIATES THE IN VITRO AND IN VIVO EFFICACY OF HORMONE MANIPULATIONS IN THE 22RV1 PROSTATE CANCER CELL MODEL . ANTICANCER RESEARCH, ISSN: 0250-7005**

**2014**

**Festuccia, C (Festuccia, Claudio), Mancini, A (Mancini, Andrea), Gravina, GL (Gravina, Giovanni Luca), Scarsella, L (Scarsella, Luca), Jitariuc, A (Jitariuc, Ana), Colapietro A, Llorens, S (Llorens, Silvia), Alonso, G (Alonso, Gonzalo), Di Cesare, E (Di Cesare, Ernesto), D'alessandro, A (D'alessandro, Anna), Carmona, M (Carmona, Manuel) (2014). ANTITUMOR EFFECTS OF SAFFRON-DERIVED CAROTENOIDS IN PROSTATE CANCER CELL MODELS . ANTICANCER RESEARCH, ISSN: 0250-7005**

2014

Festuccia, C (Festuccia, Claudio), Mancini, A (Mancini, Andrea), Scarsella, L (Scarsella, Luca), Ventura, L (Ventura, Luca), Jitariuc, A (Jitariuc, Ana), Colapietro A, Ricevuto, E (Ricevuto, Enrico), Lonning, S (Lonning, Scott), Di Cesare, E (Di Cesare, Ernesto), Gravina, GL (Gravina, Giovanni Luca) (2014). CXCR4 INHIBITION REDUCES BONE METASTASES BY AFFECTING TUMOUR GROWTH AND TUMORIGENIC POTENTIAL IN PROSTATE CANCER PRECLINICAL MODELS. ANTICANCER RESEARCH, ISSN: 0250-7005

2014

Festuccia, C (Festuccia, Claudio), Mancini, A (Mancini, Andrea), Marampon, F (Marampon, Francesco), Scarsella, L (Scarsella, Luca), Jitariuc, A (Jitariuc, Ana), Colapietro A, Di Cesare, E (Di Cesare, Ernesto), Ricevuto, E (Ricevuto, Enrico), Carnell, A (Carnell, Andrew), Gravina, GL (Gravina, Giovanni Luca) (2014). LIPID METHABOLISM AS THERAPEUTIC TARGET FOR PROSTATE CANCER. ANTICANCER RESEARCH, ISSN: 0250-7005

Gravina G.L, Mancini A, Colapietro A, Mattei V, Vitale F, Delle Monache S, Vetuschi A, Di Cesare E, Lorenzon G, Van Der aar E, Sanier L, Festuccia C. 58th Annual Meeting of the Italian Cancer Society. 5-8 September 2016, Verona, Italy.

Tyrosine kinase inhibitor, GLPG1790, blocks EphA2/Ephin-A1 signaling and is synergistic with radiotherapy and temozolomide in vivo in preclinical models of glioblastoma.

Possible Interaction Between HDACs and TGF-beta/Smads Pathway In Glioblastoma. A. Vetuschi, S. Pompili, S.Cecchinelli, A.Colapietro, A. Gallone, G. Sabetta, F. Conversi, R. Sferra. 70th Congresso della Società Italiana di Anatomia e Istologia. Roma 15-17 september 2016.

HDAC4 and HDAC6 Protect Glioblastoma Cells From Radiotherapy-Induced Cell Death. G.Gravina, F.Marampon, A.Colapietro, S.Pompili, A.Vetuschi, R.Sferra, E.Di Cesare, C.Festuccia. Società Italiana di Patologia e Medicina Traslazionale and Società Italiana di Patologia Clinica e Medicina di Laboratorio in Collaboration with The American Society for Investigative Pathology. October4-6, 2016, Montesilvanano, Pescara (PE), Italy.

**MEKs/ERKs/c-Myc Pathway Sustains EphA2 Receptor Signaling: Effect of targeting on Growth Arrest Myogenic Differentiation, and Onco-Phenotype Reversal in Rhabdomyosarcoma Cells.** A. Colapietro, G. Gravina, C.Ciccarelli, C.Dominici, F.Meggiorni, C.Festuccia, F.Marampon. Società Italiana di Patologia e Medicina Traslazionale and Società Italiana di Patologia Clinica e Medicina di Laboratorio in Collaboration with The American Society for Investigative Pathology. October4-6, 2016, Montesilvanano, Pescara (PE), Italy.

**The new alkylating histone-deacetylases inhibitor (HDACi) fusion molecule EDO-S101 shows significant MGMT expression independent antitumor activity in prclinical models of human glioblastoma and is synergistic with radiotherapy.** C. Festuccia, G.L Gravina, A.Mancini, A. Colapietro, L. Scarsella, S.Delle Monache, Y.Chen, E.Di Cesare, T. Mehrling. EACR-AACR-SIC 20-23 June, 2015 Florence, Italy.

**UNIPR, a pan ephrin receptor antagonist, impairs the glioma stem-like cells-induced vasculogenesis promoting neuronal/glial differentiation.** C. Festuccia, G. Gravina, C. Giorgio, S. Martellucci, A.Mancini, A. Colapietro, S.Delle Monache, R. Castelli, F. Vocondio, V. Mattei, A.Lodola, M. Tognolini, EACR-AACR-SIC SPECIAL CONFERENCE 2017, Florence, Italy.

## Publications

**Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.**

Gravina GL, Mancini A, **Colapietro** A, Marampon F, Sferra R, Pompili S, Biordi LA, Iorio R, Flati V, Argueta C, Landesman Y, Kauffman M, Shacham S, **Festuccia** C. Oncotarget. 2017 Nov 30;8(67):111225-111245. doi: 10.18632/oncotarget.22760.

**The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.**

Gravina GL, Mancini A, Colapietro A, Vitale F, Vetuschi A, Pompili S, Rossi G, Marampon F, Richardson PJ, Patient L, Patient L, Burbidge S, Festuccia C.

Tumour Biol. 2017 Jun;39(6):1010428317695528. doi: 10.1177/1010428317695528

**Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.**

Gravina GL, Mancini A, Mattei C, Vitale F, Marampon F, Colapietro A, Rossi G, Ventura L, Vetuschi A, Di Cesare E, Fox JA, Festuccia C.

Oncotarget. 2017 May 2;8(18):29865-29886. doi: 10.18632/oncotarget.16168.

**The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.**

Gravina GL, Mancini A, Marampon F, Colapietro A, Delle Monache S, Sferra R, Vitale F, Richardson PJ, Patient L, Burbidge S, Festuccia C.

J Hematol Oncol. 2017 Jan 5;10(1):5. doi: 10.1186/s13045-016-0377-8.

**Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.**

Marampon F, Gravina GL, Ju X, Vetuschi A, Sferra R, Casimiro MC, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.

Oncotarget. 2016 Sep 27;7(39):64526. doi: 10.18632/oncotarget.12267. No abstract available.

**Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer.**

Gravina GL, Marampon F, Sanità P, Mancini A, Colapietro A, Scarsella L, Jitariuc A, Biordi L, Ficorella C, Festuccia C.

Oncol Rep. 2016 Jul;36(1):125-30. doi: 10.3892/or.2016.4832. Epub 2016 May 23.

**c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.**

Gravina GL, Festuccia C, Popov VM, Di Rocco A, Colapietro A, Sanità P, Monache SD, Musio D, De Felice F, Di Cesare E, Tombolini V, Marampon F.

**Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.**

Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.

Oncotarget. 2016 Feb 2;7(5):5383-400. doi: 10.18632/oncotarget.6579. Erratum in: [Oncotarget. 2016 Sep 27;7\(39\):64526.](#)

**Vitamin D protects endothelial cells from irradiation-induced senescence and apoptosis by modulating MAPK/SirT1 axis.**

Marampon F, Gravina GL, Festuccia C, Popov VM, Colapietro EA, Sanità P, Musio D, De Felice F, Lenzi A, Jannini EA, Di Cesare E, Tombolini V.

J Endocrinol Invest. 2016 Apr;39(4):411-22. doi: 10.1007/s40618-015-0381-9. Epub 2015 Sep 3.

**Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.**  
Gravina GL, Mancini A, Scarsella L, Colapietro A, Jitariuc A, Vitale F, Marampon F, Ricevuto E, Festuccia C.

Tumour Biol. 2016 Jan;37(1):341-51. doi: 10.1007/s13277-015-3725-3. Epub 2015 Jul 29.



|